Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD) using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist. The active ingredient in AD04 is ondansetron, which is also the active ingredient in Zofran®, an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. Co.'s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD in genotype positive patients that does not require abstinence as part of the treatment. We show 8 historical shares outstanding datapoints in our coverage of ADIL's shares outstanding history.
Understanding the changing numbers of ADIL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADIL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADIL by allowing them to research ADIL shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
